These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 8294932)

  • 1. Neurochemical and neuroprotective effects of some aliphatic propargylamines: new selective nonamphetamine-like monoamine oxidase B inhibitors.
    Yu PH; Davis BA; Durden DA; Barber A; Terleckyj I; Nicklas WG; Boulton AA
    J Neurochem; 1994 Feb; 62(2):697-704. PubMed ID: 8294932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroprotective effects of some monoamine oxidase-B inhibitors against DSP-4-induced noradrenaline depletion in the mouse hippocampus.
    Yu PH; Davis BA; Fang J; Boulton AA
    J Neurochem; 1994 Nov; 63(5):1820-8. PubMed ID: 7931338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurochemical, neuroprotective and neurorescue effects of aliphatic N-methylpropargylamines; new MAO-B inhibitors without amphetamine-like properties.
    Yu PH; Davis BA; Zhang X; Zuo DM; Fang J; Lai CT; Li XM; Paterson IA; Boulton AA
    Prog Brain Res; 1995; 106():113-21. PubMed ID: 8584647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
    Gal S; Zheng H; Fridkin M; Youdim MB
    J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different effects of monoamine oxidase inhibition on MPTP depletion of heart and brain catecholamines in mice.
    Fuller RW; Hemrick-Luecke SK; Kindt MV; Heikkila RE
    Life Sci; 1988; 42(3):263-71. PubMed ID: 3121972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-propargylbenzylamine, a major metabolite of pargyline, is a potent inhibitor of monoamine oxidase type B in rats in vivo: a comparison with deprenyl.
    Karoum F
    Br J Pharmacol; 1987 Feb; 90(2):335-45. PubMed ID: 3103805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aliphatic propargylamines, a new series of potent selective, irreversible non-amphetamine-like MAO-B inhibitors. Their structures, function and pharmacological implications.
    Yu PH; Davis BA; Boulton AA
    Adv Exp Med Biol; 1995; 363():17-23. PubMed ID: 7618520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors.
    Yu PH; Davis BA; Boulton AA
    J Med Chem; 1992 Oct; 35(20):3705-13. PubMed ID: 1433183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine], a new MAO-B inhibitor, attenuates MPTP-induced depletion of striatal dopamine levels in C57/BL6 mice.
    Perez V; Unzeta M
    Neurochem Int; 2003 Feb; 42(3):221-9. PubMed ID: 12427476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potentiation of para-hydroxyamphetamine-induced head-twitch response by inhibition of monoamine oxidase type A in the brain.
    Tadano T; Satoh S; Satoh N; Kisara K; Arai Y; Kim SK; Kinemuchi H
    J Pharmacol Exp Ther; 1989 Jul; 250(1):254-60. PubMed ID: 2501477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the effects of two 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs, 1-methyl-4-(2-thienyl)-1,2,3,6-tetrahydropyridine and 1-methyl-4-(3-thienyl)-1,2,3,6-tetrahydropyridine, on monoamine oxidase in vitro and on dopamine in mouse brain.
    Fuller RW; Robertson DW; Hemrick-Luecke SK
    J Pharmacol Exp Ther; 1987 Feb; 240(2):415-20. PubMed ID: 3100775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of MAO B, but not MAO A, blocks DSP-4 toxicity on central NE neurons.
    Gibson CJ
    Eur J Pharmacol; 1987 Sep; 141(1):135-8. PubMed ID: 3117577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical evidence of neuroprotection by R(-)-deprenyl and N-(2-hexyl)-N-methylpropargylamine on DSP-4-induced degeneration of rat brain noradrenergic axons and terminals.
    Zhang X; Zuo DM; Davis BA; Boulton AA; Yu PH
    J Neurosci Res; 1996 Feb; 43(4):482-9. PubMed ID: 8699534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of structural modification of alkyl N-propargylamines on the selective inhibition of monoamine oxidase B activity.
    Yu PH; Davis BA; Boulton AA
    Biochem Pharmacol; 1993 Aug; 46(4):753-7. PubMed ID: 8363648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.
    Riederer P; Youdim MB
    J Neurochem; 1986 May; 46(5):1359-65. PubMed ID: 2420928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of kaempferol as a monoamine oxidase inhibitor and potential Neuroprotectant in extracts of Ginkgo biloba leaves.
    Sloley BD; Urichuk LJ; Morley P; Durkin J; Shan JJ; Pang PK; Coutts RT
    J Pharm Pharmacol; 2000 Apr; 52(4):451-9. PubMed ID: 10813558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.
    Aubin N; Barneoud P; Carter C; Caille D; Sontag N; Marc C; Lolivier J; Gardes A; Perron C; Le Kim A; Charieras T; Pandini M; Burnier P; Puech F; Jegham S; George P; Scatton B; Curet O
    J Pharmacol Exp Ther; 2004 Sep; 310(3):1171-82. PubMed ID: 15178694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A study of the biological pharmacology of IFO, a new selective and reversible monoamine oxidase-B inhibitor.
    Matsumoto J; Takahashi T; Agata M; Toyofuku H; Sasada N
    Jpn J Pharmacol; 1994 May; 65(1):51-7. PubMed ID: 8089930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The molecular pharmacology of L-deprenyl.
    Gerlach M; Riederer P; Youdim MB
    Eur J Pharmacol; 1992 Jun; 226(2):97-108. PubMed ID: 1639115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amphetamine-metabolites of deprenyl involved in protection against neurotoxicity induced by MPTP and 2'-methyl-MPTP.
    Sziráki I; Kardos V; Patthy M; Pátfalusi M; Gaál J; Solti M; Kollár E; Singer J
    J Neural Transm Suppl; 1994; 41():207-19. PubMed ID: 7931228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.